CD5 and CD6 Immunobiology: Multitask Immunomodulatory Molecules in Infection, Cancer and Autoimmunity
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: 13 February 2026 | Viewed by 12
Special Issue Editors
2. Servei d’Immunologia, Hospital Clínic de Barcleona, 08036 Barcelona Spain
3. Immunereceptors of the Innate and Adaptive System’s Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDBAPS), 08036 Barcelona, Spain
Interests: infection; immunotherapy; lymphoid scavenger receptor; T cell activation; cancer; autoimmunity
Special Issues, Collections and Topics in MDPI journals
Interests: cancer; autoimmunity; fungal, bacterial and parasitic infection; immunotherapy; lymphoid scavenger receptors; T and NK cell immunomodulation
Special Issue Information
Dear Colleagues,
Despite being among the first lymphocyte surface receptors identified thanks to the advent of monoclonal antibody technology, the immunobiology of CD5 and CD6 still remains incompletely understood. Although they were initially identified as costimulatory molecules expressed in T lymphocytes and a subpopulation of B lymphocytes, later work in knockout mice showed that this was a simplistic view and not entirely accurate. On the one hand, both molecules were shown to be physically associated with antigen-specific clonotypic receptor complexes from T (TCR/CD3) and B1a (BCR) cells and capable of fine-tuning (either negatively or positively) the activation and differentiation signals mediated by such relevant receptors. On the other hand, we later learned that CD5 and CD6 expression also extend to other quantitatively minor but functionally relevant cell subsets (e.g., macrophages, dendritic cells, NK cells) and that the interacting partners of CD5 and CD6 include not only endogenous counterreceptors but also conserved pathogen-associated structures of bacterial, parasitic, fungal, or viral origin. All of this means thar CD5 and CD6 are important regulators of the immune responses to non-self (infectious), modified-self (tumor), and self (auto-) antigens, opening up new avenues in the development of alternative CD5- and CD6-based immunomodulatory strategies tailored to currently unresolved clinical needs. For this Special Issue, we invite submissions on recent advances in the immunobiology of CD5 and CD6 receptors relevant to the pathophysiology and treatment of infectious, neoplastic, and autoimmune disorders.
Dr. Lozano Francisco
Dr. María Velasco-de Andrés
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CD5
- CD6
- T cells
- B1a cells
- NK cells
- immunomodulation
- infection
- cancer
- autoimmunity
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
